Full Prescribing Information for OXLUMO® (lumasiran)
Click below to learn more about the use of lumasiran in pediatric and adult patients with primary hyperoxaluria type 1 (PH1).
If you require any further information on lumasiran, please connect with us by reaching out to your local Medical Science Liaison or contacting our Medical Information team.
For more information about data regarding lumasiran, please visit our Congresses and Publications resource page.
Intended for US healthcare professionals. This site is intended to provide balanced, evidence-based information to support scientific exchange. It is not intended to provide medical advice or recommendations for clinical practice.
Information about investigational therapeutics or investigational uses of approved products does not establish the safety or efficacy of these therapeutics or uses, and there is no guarantee of FDA approval.
Alnylam does not recommend or suggest use of its products in any manner inconsistent with the approved Prescribing Information.
Are you a healthcare professional practicing in the United States?
I confirm I am a US healthcare professional
I am a US payer or healthcare decision maker
I am not a US healthcare professional, or a US payer or healthcare decision maker